PL1885339T3 - Formulacje inhibitora src/abl - Google Patents

Formulacje inhibitora src/abl

Info

Publication number: PL1885339T3
Authority: PL; Poland
Prior art keywords: src; formulations; abl inhibitor; abl; inhibitor
Prior art date: 2005-05-05

Application number

PL06769997T

Other languages

English (en)

Inventor

Julia Zh Gao

Rajeshwar Motheram

Original Assignee

Bristol Myers Squibb Holdings Ireland

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-05-05

Filing date

2006-05-04

Publication date

2015-12-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37076246&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1885339(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-05-04 Application filed by Bristol Myers Squibb Holdings Ireland filed Critical Bristol Myers Squibb Holdings Ireland

2015-12-31 Publication of PL1885339T3 publication Critical patent/PL1885339T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Hematology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PL06769997T 2005-05-05 2006-05-04 Formulacje inhibitora src/abl PL1885339T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US67803005P	2005-05-05	2005-05-05
PCT/US2006/017073 WO2006121742A2 (en)	2005-05-05	2006-05-04	Formulations of a src/abl inhibitor
EP06769997.5A EP1885339B1 (en)	2005-05-05	2006-05-04	Formulations of a src/abl inhibitor

Publications (1)

Publication Number	Publication Date
PL1885339T3 true PL1885339T3 (pl)	2015-12-31

Family

ID=37076246

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL06769997T PL1885339T3 (pl)	2005-05-05	2006-05-04	Formulacje inhibitora src/abl

Country Status (18)

Country	Link
US (2)	US20060251723A1 (pl)
EP (1)	EP1885339B1 (pl)
JP (1)	JP5173794B2 (pl)
CN (2)	CN102813655A (pl)
AR (1)	AR054445A1 (pl)
DK (1)	DK1885339T3 (pl)
ES (1)	ES2546847T3 (pl)
GE (1)	GEP20104927B (pl)
HR (1)	HRP20151051T1 (pl)
HU (1)	HUE026040T2 (pl)
NO (1)	NO343939B1 (pl)
PE (1)	PE20061373A1 (pl)
PL (1)	PL1885339T3 (pl)
PT (1)	PT1885339E (pl)
RS (1)	RS54258B1 (pl)
SI (1)	SI1885339T1 (pl)
TW (1)	TWI386205B (pl)
WO (1)	WO2006121742A2 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ID30460A (id)	1999-04-15	2001-12-06	Bristol Myers Squibb Co	Inhibitor-inhibitor protein siklik tirosin kinase
PT1885339E (pt)	2005-05-05	2015-10-12	Bristol Myers Squibb Holdings Ireland	Formulações de um inibidor src/abl
WO2006135790A1 (en) *	2005-06-09	2006-12-21	Bristol-Myers Squibb Company	Methods of identifying and treating individuals exhibiting mutant kit protein
EP1937270A1 (en) *	2005-09-21	2008-07-02	Brystol-Myers Squibb Company	Oral administration of n-(2-chloro-6-methylphenyl)-2-[[6-4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof
WO2007109527A1 (en) *	2006-03-17	2007-09-27	Bristol-Myers Squibb Company	Methods of identifying and treating individuals exhibiting mutant bcr/abl kinase polypeptides
EP2132173B1 (en) *	2007-02-26	2015-10-07	Merck Sharp & Dohme Corp.	Formulations for cathepsin k inhibitors
EP2359813A1 (en)	2010-02-04	2011-08-24	Ratiopharm GmbH	Pharmaceutical composition comprising N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamid
CN101891738B (zh)	2010-02-08	2011-09-28	南京卡文迪许生物工程技术有限公司	达沙替尼多晶型物及其制备方法和药用组合物
JP5589097B2 (ja) *	2010-02-08	2014-09-10	南京▲か▼文迪許生物工程技術有限公司	ダサチニブ多結晶体、並びにその調製方法及び薬物組成物
CN104274420B (zh) *	2013-07-11	2019-03-05	石药集团中奇制药技术（石家庄）有限公司	一种达沙替尼组合物及其制备方法
IN2013MU03610A (pl)	2013-12-18	2015-04-24	Dharmesh Mahendrabhai Shah
EP3419605A1 (en)	2016-02-25	2019-01-02	Remedica Ltd	Dasatinib formulation
JP7166754B2 (ja)	2017-11-22	2022-11-08	沢井製薬株式会社	ダサチニブ無水物含有製剤
JP7249397B2 (ja) *	2017-12-27	2023-03-30	日本化薬株式会社	ダサチニブを有効成分とする医薬組成物
JP7000148B2 (ja) *	2017-12-27	2022-01-19	日本化薬株式会社	ダサチニブを有効成分とする医薬組成物
WO2020018053A2 (en) *	2018-05-25	2020-01-23	Arven Ilac Sanayi Ve Ticaret Anonim Sirketi	The tablet comprising dasatinib
TWI770624B (zh)	2018-06-15	2022-07-11	漢達生技醫藥股份有限公司	尼洛替尼十二烷基硫酸鹽在製備用於治療慢性骨髓性白血病之劑型的用途
GB2592680A (en)	2020-03-06	2021-09-08	Zentiva Ks	Pharmaceutical compositions comprising dasatinib anhydrous and uses thereof
EP4071248A1 (en)	2021-04-07	2022-10-12	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Means and methods for enhancing receptor-targeted gene transfer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3539380A (en)	1968-01-08	1970-11-10	Upjohn Co	Methylcellulose and polyalkylene glycol coating of solid medicinal dosage forms
US4543370A (en)	1979-11-29	1985-09-24	Colorcon, Inc.	Dry edible film coating composition, method and coating form
US5681382A (en)	1995-08-22	1997-10-28	Shin-Etsu Chemical Co., Ltd.	Rapidly soluble coating composition and method for preparing same
AR016827A1 (es) *	1997-08-22	2001-08-01	Smithkline Beecham Corp	PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
ID30460A (id)	1999-04-15	2001-12-06	Bristol Myers Squibb Co	Inhibitor-inhibitor protein siklik tirosin kinase
US7125875B2 (en) *	1999-04-15	2006-10-24	Bristol-Myers Squibb Company	Cyclic protein tyrosine kinase inhibitors
BR0008059A (pt) *	1999-12-08	2002-03-26	Pharmacia Corp	Composições de valdecoxib
GB0209257D0 (en) *	2002-04-23	2002-06-05	Novartis Ag	Organic compounds
US20050215795A1 (en) *	2004-02-06	2005-09-29	Bang-Chi Chen	Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
US7491725B2 (en) *	2004-02-06	2009-02-17	Bristol-Myers Squibb Company	Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
TWI338004B (en) *	2004-02-06	2011-03-01	Bristol Myers Squibb Co	Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
PT1885339E (pt)	2005-05-05	2015-10-12	Bristol Myers Squibb Holdings Ireland	Formulações de um inibidor src/abl

2006
- 2006-05-04 PT PT67699975T patent/PT1885339E/pt unknown
- 2006-05-04 CN CN2012103135834A patent/CN102813655A/zh active Pending
- 2006-05-04 AR ARP060101816A patent/AR054445A1/es not_active Application Discontinuation
- 2006-05-04 ES ES06769997.5T patent/ES2546847T3/es active Active
- 2006-05-04 US US11/418,338 patent/US20060251723A1/en not_active Abandoned
- 2006-05-04 SI SI200631971T patent/SI1885339T1/sl unknown
- 2006-05-04 HR HRP20151051TT patent/HRP20151051T1/hr unknown
- 2006-05-04 WO PCT/US2006/017073 patent/WO2006121742A2/en not_active Ceased
- 2006-05-04 DK DK06769997.5T patent/DK1885339T3/en active
- 2006-05-04 HU HUE06769997A patent/HUE026040T2/en unknown
- 2006-05-04 RS RS20150635A patent/RS54258B1/sr unknown
- 2006-05-04 EP EP06769997.5A patent/EP1885339B1/en not_active Revoked
- 2006-05-04 GE GEAP200610410A patent/GEP20104927B/en unknown
- 2006-05-04 JP JP2008510188A patent/JP5173794B2/ja active Active
- 2006-05-04 PL PL06769997T patent/PL1885339T3/pl unknown
- 2006-05-04 CN CNA2006800150680A patent/CN101170996A/zh active Pending
- 2006-05-05 PE PE2006000477A patent/PE20061373A1/es not_active Application Discontinuation
- 2006-05-05 TW TW095116078A patent/TWI386205B/zh active
2007
- 2007-10-10 NO NO20075154A patent/NO343939B1/no unknown
2013
- 2013-01-07 US US13/735,081 patent/US20130122093A1/en not_active Abandoned

Also Published As

Publication number	Publication date
RS54258B1 (sr)	2016-02-29
EP1885339A2 (en)	2008-02-13
CN102813655A (zh)	2012-12-12
NO20075154L (no)	2008-02-01
EP1885339B1 (en)	2015-07-29
JP5173794B2 (ja)	2013-04-03
WO2006121742A3 (en)	2007-02-22
US20130122093A1 (en)	2013-05-16
WO2006121742A2 (en)	2006-11-16
HUE026040T2 (en)	2016-05-30
PT1885339E (pt)	2015-10-12
ES2546847T3 (es)	2015-09-29
DK1885339T3 (en)	2015-10-19
NO343939B1 (no)	2019-07-15
HRP20151051T1 (hr)	2015-11-06
CN101170996A (zh)	2008-04-30
JP2008540440A (ja)	2008-11-20
AR054445A1 (es)	2007-06-27
TW200716117A (en)	2007-05-01
SI1885339T1 (sl)	2015-10-30
GEP20104927B (en)	2010-03-25
US20060251723A1 (en)	2006-11-09
PE20061373A1 (es)	2006-12-15
TWI386205B (zh)	2013-02-21

Publication	Publication Date	Title
ZA200802585B (en)	2009-02-25	Pyridopyrimidinone inhibitors of Pl3Kα
IL190292A0 (en)	2009-09-22	PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka
PT1885339E (pt)	2015-10-12	Formulações de um inibidor src/abl
IL184303A0 (en)	2007-10-31	Amino-pyridines as inhibitors of ??-secretase
IL195030A0 (en)	2009-08-03	Dpp iv inhibitor formulations
PL2079727T3 (pl)	2016-08-31	Inhibitory kinazy
PL2402317T3 (pl)	2013-11-29	Inhibitor DGAT
IL185185A0 (en)	2007-12-03	Azolylacylguanidines as ??-secretase inhibitors
PT2094708E (pt)	2014-01-07	Pirrolopirazina como inibidor da cinase syk
ZA200702394B (en)	2008-11-26	Indozolone derivatives as 11b-HSD1 inhibitors
ZA200700181B (en)	2009-03-25	Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
IL184569A0 (en)	2007-10-31	Intravenous formulations of pde-5 inhibitors
ZA200707070B (en)	2008-09-25	Analgesic compositions
EP2036894A4 (en)	2011-01-12	AURORA INHIBITOR
GB0504995D0 (en)	2005-04-20	Use of a compound
EP1941873A4 (en)	2012-09-26	METALLO-BETA-Lactamase INHIBITORS
EP2098544A4 (en)	2013-10-16	POLYMERIZABLE COMPOUNDS AND POLYMERIZABLE COMPOSITIONS
EP2036893A4 (en)	2011-04-13	ABL Kinase Inhibitor
AP2007004282A0 (en)	2007-12-31	Derivatives of A 1-phenyltriazole as antiparasiticagents
EP1728515A4 (en)	2009-03-18	INHIBITOR OF INFLUENZA VIRUS INFECTION
GB0516967D0 (en)	2005-09-28	Inhibitors
GB0512626D0 (en)	2005-07-27	Inhibitor compounds
GB0517677D0 (en)	2005-10-05	Inhibitor compounds II
GB0522829D0 (en)	2005-12-21	Use of a compound
HUP0500461A3 (en)	2009-04-28	Pyperazine derivatives of alkyl-oxindoles